Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: Can the burden of intrathecal methotrexate be reduced?

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 467-475

  Niemann, Andreas ^a   Mühlisch, Jörg ^a   Frühwald, Michael C ^b   Gerß, Joachim ^b   Hempel, Georg ^a,c   Boos, Joachim ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Departments of Medical Informatics and Biomathematics   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

acute lymphoblastic leukemia; cerebrospinal fluid; children; intrathecal; methotrexate; therapeutic drug monitoring

Indexed keywords

7 HYDROXYMETHOTREXATE; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG MONITORING; FEMALE; HUMAN; INFANT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHOOL CHILD; AGING; BIOTRANSFORMATION; BLOOD; CEREBROSPINAL FLUID; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MASS SPECTROMETRY; METABOLISM; NEOPLASMS; RETROSPECTIVE STUDY; RISK ASSESSMENT; YOUNG ADULT;

ADOLESCENT; AGING; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; INJECTIONS, SPINAL; LEUKEMIA; MASS SPECTROMETRY; METHOTREXATE; NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 77955174464     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181e5c6b3     Document Type: Article

References (52)

1. Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93: 361-366.
2. Djerassi I, Farber S, Abir E, et al. Continuous infusion of methotrexate in children with acute leukemia. Cancer. 1967;20:233-242.
3. Moe PJ, Holen A. High-dose methotrexate in childhood ALL. Pediatr Hematol Oncol. 2000;17:615-622.
4. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol. 1989;11:74-86.
5. Blaney SM, Poplack DG. Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs. 1996;14:69-85.
6. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21:1798-1809.
7. Ochs J, Mulhern R. Long-term sequelae of therapy for childhood acute lymphoblastic leukaemia. Baillieres Clin Haematol. 1994;7:365-376.
8. Cap J, Foltinova A, Kaiserova E, et al. Is high dose methotrexate without irradiation of the brain sufficiently effective in prevention of CNS disease in children with acute lymphoblastic leukemia? Neoplasma. 1998;45: 176-179.
9. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730-2741.
10. Keidan I, Bielorei B, Berkenstadt H, et al. Prospective evaluation of clinical and laboratory effects of intrathecal chemotherapy on children with acute leukemia. J Pediatr Hematol Oncol. 2005;27:307-310.
11. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111: 4477-4489.
12. Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest. 1969;48:2140-2155.
13. 2 in children with acute lymphoblastic leukemia. Cancer. 1987;60:5-13.
14. Jonsson P, Hoglund P, Wiebe T, et al. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia. Anticancer Drugs. 2007;18:941-948.
15. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16:1561-1567.
16. Vassal G, Valteau D, Bonnay M, et al. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma. Pediatr Hematol Oncol. 1990;7:71-77.
17. 2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group. Eur J Cancer. 1990;26:492-495.
18. 2 methotrexate. Leuk Lymphoma. 1994;14:141-144.
19. Seidel H, Andersen A, Kvaloy JT, et al. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. Leuk Res. 2000;24:193-199.
20. Evans WE, Hutson PR, Stewart CF, et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther. 1983;33:301-307.
21. Lippens RJ, Winograd B. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction. Pediatr Hematol Oncol. 1988;5:115-124.
22. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161-166.
23. Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet. 2002;41:171-186.
24. FDA. Guidance for Industry: Bioanalytical Method Validation. 2001 Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM070107.pdf. Accessed December 18, 2009.
25. Oka K, Yamamoto M, Nonaka T, et al. The significance of artificial cerebrospinal fluid as perfusate and endoneurosurgery. Neurosurgery. 1996;38:733-736.
26. Balis FM, Savitch JL, Bleyer WA, et al. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol. 1985;3: 485-489.
27. Thyss A, Milano G, Deville A, et al. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol. 1987;23:843-847.
28. Chatelut E, Roche H, Plusquellec Y, et al. Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children. J Pharm Sci. 1991;80:730-734.
29. Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg. 1999;91:221-230.
30. Donelli MG, Zucchetti M, Robatto A, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol. 1995;24:154-159.
31. Jacobs SA, Stoller RG, Chabner BA, et al. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest. 1976;57:534-538.
32. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4:87-101.
33. Lankelma J, van der KE, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett. 1980;9:133-142.
34. Fabre G, Cano JP, Iliadis A, et al. Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study. J Pharm Biomed Anal. 1984;2:61-72.
35. 2 to children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1990;18:217-224.
36. Payet B, Tubiana N, Lejeune C, et al. High-dose methotrexate: methotrexate and 7-hydroxymethotrexate diffusion in cerebrospinal fluid. Int J Cancer. 1988;42:135-136.
37. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973;52:1804-1811.
38. Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;309:1094-1104.
39. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975;195:73-83.
40. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973;289:770-773.
41. Bleyer WA, Dedrick RL. Clinical pharmacology of intrathecal metho-trexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep. 1977;61:703-708.
42. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol. 1989;11:93-105.
43. Bay A, Oner AF, Etlik O, et al. Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol. 2005;27: 270-272.
44. Boran P, Tokuc G, Boran BO, et al. Intracerebral hematoma as a complication of intrathecal methotrexate administration. Pediatr Blood Cancer. 2008;50:152-154.
45. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following in-traventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet. 2005;44:1-31.
46. Ettinger LJ, Chervinsky DS, Freeman AI, et al. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer. 1982;50:1676-1682.
47. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacody-namics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986;314:471-477.
48. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5:2017-2031.
49. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9: 257-268.
50. Burger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184-188.
51. Woessmann W, Seidemann K, Mann G, et al. The impact of the metho-trexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948-958.
52. Brugieres L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897-903.